Clinical contexts in which SEGLENTIS may be appropriate

Turn to SEGLENTIS when:

Delivering adequate
acute pain relief with
nonopioids is unlikely3

Going past the point of
diminishing returns in
acute pain relief (more
than 50 MME/day) is a

Addressing inflammation is necessary in managing acute pain1

Looking for durable 12‑hour dosing and extended pain relief1

Increased abuse risk of
Schedule II opioids is a
major concern4

View the unique pharmacokinetics of SEGLENTIS

View PK data

References: 1. Seglentis [prescribing information]. Montgomery, AL: Kowa Pharmaceuticals America, Inc.; October 2021. 2. Viscusi ER, de Leon-Casasola O, Cebrecos J, et al. Celecoxibtramadol co-crystal in patients with moderate-to-severe pain following bunionectomy with osteotomy: a phase 3, randomized, double-blind, factorial, active- and placebo-controlled trial. Pain Pract. 2023;23(1):8-22. doi:10.1111/papr.13136. Epub 2022 Jul 8. PMID: 35686380 3. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95. doi:10.15585/mmwr.rr7103a1 4. United States Drug Enforcement Administration. Drug scheduling. Accessed March 28, 2023.